KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,883 INR | -0.85% |
|
+2.96% | -4.78% |
| 05-31 | Krishna Institute of Medical Sciences Signs Deal to Set Up New Hospital in Bengaluru, India | MT |
| 05-21 | Krishna Institute of Medical Sciences to Invest Up to INR713 Million in Wholly Owned Arm | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- With an expected P/E ratio at 45.53 and 41.01 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.78% | 1.82B | C- | ||
| +24.27% | 88.24B | C+ | ||
| -23.86% | 76.2B | B- | ||
| +1.76% | 26.63B | C+ | ||
| +8.05% | 18.14B | A- | ||
| -12.91% | 16.69B | B | ||
| +3.81% | 15.85B | A- | ||
| +76.50% | 13.61B | C- | ||
| +78.07% | 13.24B | C+ | ||
| +37.75% | 12.72B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- KIMS Stock
- KIMS Stock
- Ratings Krishna Institute of Medical Sciences Limited